ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)

被引：1
|
作者：
Gomella, Leonard G.
Chi, Kim N.
de Bono, Johann S.
Fizazi, Karim
Miller, Kurt
Rathkopf, Dana E.
Ryan, Charles J.
Scher, Howard I.
Shore, Neal D.
De Porre, Peter
Londhe, Anil
McGowan, Tracy
Pelhivanov, Nonko
Charnas, Robert
Todd, Mary B.
Montgomery, Bruce
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.1963
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP87-18
引用
收藏
页码：E1091 / E1091
页数：1
相关论文
共 50 条
  • [41] Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: The results from IMAAGEN core study.
    Ryan, Charles J.
    Crawford, E. David
    Shore, Neal D.
    Underwood, Willie
    Wang, Jim
    DePalantino, Jannell
    Londhe, Anil
    Yang, Zandong
    McGowan, Tracy
    Kantoff, Philip W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis.
    Tucci, Marcello
    Vignani, Francesca
    Bertaglia, Valentina
    Buttigliero, Consuelo
    Berruti, Alfredo
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).
    Caffo, Orazio
    Frantellizzi, Viviana
    Tucci, Marcello
    Galli, Luca
    Monari, Fabio
    Baldari, Sergio
    Masini, Cristina
    Bortolus, Roberto
    Facchini, Gaetano
    Alongi, Pierpaolo
    Zichi, Clizia
    Biasco, Elisa
    Fanti, Stefano
    Pignata, Salvatore
    Filice, Angelina
    Borsatti, Eugenio
    Rossetti, Sabrina
    Spada, Massimiliano
    Cortesi, Enrico
    De Vincentis, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer
    Chen, Hung-Kai
    Su, Po-Jung
    Wang, Yan-Lin
    Chang, Kai-Cheng
    Su, Yu-Li
    Chang, Pei-Hung
    Kuan, Feng-Che
    Hsieh, Chia-Hsun
    Kuo, Yung-Chia
    Sheng, Ting-Wen
    Chang, Ching-Fu
    Yu, Shao-Ming
    Huang, Wen-Kuan
    Lin, Yung-Chang
    Tsan, Din-Li
    Yu, Kai-Jie
    Lin, Po-Hung
    Chen, Hui-Yu
    Chang, Ying-Hsu
    Pang, See-Tong
    Chuang, Cheng-Keng
    Lai, Edward Chia-Cheng
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (06) : 1191 - 1201
  • [45] Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience
    Fiala, Ondrej
    Hosek, Petr
    Korunkova, Hana
    Hora, Milan
    Kolar, Jiri
    Windrichova, Jindra
    Sorejs, Ondrej
    Topolcan, Ondrej
    Travnicek, Ivan
    Sedlackova, Hana
    Finek, Jindrich
    [J]. ANTICANCER RESEARCH, 2023, 43 (01) : 463 - 471
  • [46] Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA plus P): Patient characteristics and treatment persistence.
    Moses, Kelvin A.
    Penson, David F.
    Schultz, Neil M.
    Shi, Fei
    Wilson, Samuel
    Brown, Bruce A.
    Barlev, Arie
    Flanders, Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)
    Montgomery, Robert B.
    San Kheoh, Thian
    Molina, Arturo
    Li, Jinhui
    Bellmunt, Joaquim
    Ryan, Charles J.
    Namphuong Tran
    Loriot, Yohann
    Efstathiou, Eleni
    Scher, Howard I.
    De Bono, Johann Sebastian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Long-term outcomes and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) showing abiraterone withdrawal syndrome (AWS) after docetaxel (DOC) treatment.
    Caffo, Orazio
    Maines, Francesca
    Trentin, Chiara
    Veccia, Antonello
    Galligioni, Enzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [49] Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone ( plus P/D).
    Shen, Dong
    Thomas, Shibu
    Lefresne, Florence
    Gormley, Michael
    Urtishak, Karen
    Lahaye, Marjolein
    Tombal, Bertrand F.
    Merseburger, Axel S.
    Parekh, Trilok V.
    Ricci, Deborah S.
    Attard, Gerhardt
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302
    Smith, Matthew R.
    Matheny, Shannon
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    De Bono, Johann Sebastian
    Small, Eric Jay
    Shore, Neal D.
    Fizazi, Karim
    Kheoh, Thian San
    Li, Jinhui
    Todd, Mary Beth
    Griffin, Thomas W.
    Yu, Margaret K.
    Ryan, Charles J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345